A tremendous amount of gene sequence data is now available due to the efforts of many independent labs and the Human Genome Project. Armed with this information, scientists are now focusing on gene ...
Venlo, the Netherlands, Nov. 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its sample technologies portfolio with the introduction of ...
Momentum building as QIAGEN prepares for three important new instrument launches in 2025 and 2026: QIAsymphony Connect, QIAsprint and QIAmini QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today ...
Pioneering next-level sample processing with connectivity, simplicity, and unmatched flexibility Building on the success of EZ1 technology, three versions offer application area tailored value ...
Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for ...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its NeuMoDx™ HAdV Quant Assay for the identification and quantification ...
Venlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced key updates to its sample technologies solutions for non-invasive liquid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback